HR and triple-negative breast carcinoma: Out of 349 patients treated with chemotherapy regimens, anthracycline and taxane-based regimen was the most frequently used chemotherapy regimen in all subgroups (both in pN0 and pN-positive): for 43/84 (51.2%) HER2+/HR+ patients, 11/25 (44.0%) HER2+/HR-negative patients, 143/177 (80.8%) HER2-negative/HR+ patients, and 47/63 (74.6%) triple negative breast cancer patients.